1. Introduction {#sec1}
===============

The multi component dosage forms has lot of importance due to greater patients acceptability, multiple action and quick relief from the multi-disease. Telmisartan (TMS) is an angiotension receptor blocker that shows high affinity from the angiotensin II type 1-receptors, has a long duration of action, and has the longest half-life of an ARB. In addition to blocking the Renin-Angiotensin System (RAS), TMS acts as a selective modulator of Peroxisome proliferator-activated receptor gamma (PPAR-γ), a central regulator of insulin and glucose metabolism. Hydrochlorothiazide (HCZ) is a diuretic (water pill) drug that help to control blood pressure by getting rid of excess salt and water. In the present study, TMS and HCZ in a bilayer tablet formulation was used to evaluate the chromatographic separation of TMS, HCZ and its related impurities..

TMS, a non-peptide molecule, is chemically described as 4'-\[(1, 4′-dimethyl-2′-propyl \[2, 6′-bi-1Hbenzimidazol\]-1′-yl) methyl\]-\[1, 1′-biphenyl\]-2-carboxylic acid and empirical formula is C~33~H~30~N~4~O~2.~ TMS has a pKa of 6 and practically insoluble in water and in the pH range of 3--9, sparingly soluble in strong acid (except insoluble in hydrochloric acid), soluble in strong base (e.g. Sodium hydroxide - about 12 ​mg ​mL^-1^), slightly soluble in methanol, sparingly soluble in methylene chloride \[[@bib1]\].

HCZ is chemically described as 6-chloro-3, 4-dihydro-2H-1, 2, 4-benzothiadiazine-7 sulfonamide 1,1-dioxide and empirical formula is C~7~H~8~ClN~3~O~4~S~2.~ HCZ is a white, or practically white, practically odorless, crystalline powder. It has a pKa of 7.9 and the solubility in water is about 0.7 ​mg ​mL^-1^ and freely soluble in sodium hydroxide solution \[[@bib1]\]. The structures of HCZ and TMS compounds with specified impurities are shown in [Fig. 1](#fig1){ref-type="fig"}. The immediate release tablets required a hydrophilic and hydrophobic excipient to enhance the disintegration and flowability of powder. Lubricant like magnesium stearate excipients influence the extraction of test solution. All these inactive ingredients influence the actual selectivity of the HPLC method development during in-vitro determinations and stability studies.Fig. 1Chemical Structures of TMS, HCZ and its impurities.Fig. 1

Literature reveals various HPLC methods have been reported with human plasma and with the combination of other active drug compounds \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9]\]. Very limited methods have been reported for the quantification impurities of TMS alone or with combination of TMS and HCZ impurities \[[@bib10], [@bib11], [@bib12]\]^.^ The selectivity and sensitivity were not effective in the listed articles in terms of impurities evaluations. In the published literature, none of these methods that were found relevant to the application of estimation of all possible relevant impurities. There was only one method \[[@bib13]\] is published with 9 impurities (7 impurities of TMS, 2 impurities of HCZ) which did not report 4 other process degradant impurities of the active drug substance. From the overall literature, there was no method which can determine the stated impurities of the both active components including the process degradant impurities of the active drug components. Hence, we developed and validated a unique harmonized stability indicating method \[[@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24]\] for specific determination of listed related compounds of TMS and HCTZ simultaneously in drug substance and drug product tablet dosage form.

2. Materials and methods {#sec2}
========================

2.1. Chemicals and reagents {#sec2.1}
---------------------------

TMS (purity-99.2%) and impurities are TMS-EP-A, TMS-EP-B, TMS-EP-C, TMS-EP-D, TMS-EP-E, TMS-EP-F, TMS-EP-G and TMS-EP-H official in European Pharmacopoeia. TMS-EP-C is a process related impurity and TMS-EP-D is unspecified impurity. Chloro analogue, Diacid and TEL-2/TMS-2 are API process impurities. TMS-EP-A, TMS-EP-B, Chloro analogue, Diacid and TMS-2 are obtained from Dr. Reddy's laboratories Ltd. Potassium dihydrogen phosphate AR Grade-Merck (India) limited. HCZ (purity-99.5%), Chlorothiazide (CTZ) and Disulphonamide (DSA), TMS-EP-E and TMS-EP-F are obtained from Synpure Laboratories.

All other chemicals and solvents used as Analytical/HPLC grade. The analysis was carried out on Waters Alliance HPLC systems 2695 separation module connected to 2996 Photo diode array detector. Data acquisition was carried out using Empower software. Different chromatographic columns used during initial method optimization viz. Kromosil C18, 125 ​× ​4.0 ​mm, 5 ​μm, Waters Symmetry Shield RP-18, 250 ​× ​4.6 ​mm, 5 ​μm and Inertsil ODS 3 ​V, 150 ​× ​4.6 ​mm, 3.5 ​μm (make-GL Sciences).

2.2. Chromatographic conditions {#sec2.2}
-------------------------------

The separation of TMS, HCZ and all related impurities were achieved using 20 ​mM Potassium dihydrogen phosphate buffer, pH adjusted to 3.5 using 1% Ortho phosphoric acid solution as mobile phase-A. Purified water and acetonitrile in the ratio of 100:900 as mobile phase--B at a flow rate of 1.0 ​mL/min with a gradient elution method (For Gradient proportions, refer [Table 1](#tbl1){ref-type="table"}). Detection and purity establishment of the main drug and impurities were achieved using photo diode array (PDA) detector at 230 ​nm with an injection volume of 10 ​μL and column temperature is 40 ​°C. The run time optimized was found to be 65 ​min.Table 1Gradient program.Table 1Time (Min)% A% B0851528515126535305050404060502080510100600100618515658515

2.3. Standard preparation (0.3%) {#sec2.3}
--------------------------------

The dilute standard solution for TMS and HCZ was prepared with diluent to obtain a concentration of 1.5 ​μg/mL and 0.6 ​μg/mL, respectively. Representative chromatograms of the blank and standard preparation were shown in [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3A](#fig3a){ref-type="fig"}, [Fig. 3B](#fig3b){ref-type="fig"}. The system suitability and chromatographic evaluation is represented in [Table 2](#tbl2){ref-type="table"}.Fig. 2Blank Chromatogram.*Legend: Flow rate 1.*0 ​mL/min*, UV Wavelength* 230 ​nm*; injection volume* 10 ​μL; ***Column temperature 30***°C; *Gradient Elution; Run time:* 65 ​min.Fig. 2Fig. 3ADiluted standard chromatogram.Legend: Flow rate 1.0 ​mL/min*, UV Wavelength* 230 ​nm*; injection volume* 10 ​μL; ***Column temperature 30***°C*; Gradient Elution; Run time:* 65 ​min.Fig. 3AFig. 3BTelmisartan EP CRS solution chromatogram.Legend: Flow rate 1.0 ​mL/min*, UV Wavelength* 230 ​nm*; injection volume* 10 ​μL; ***Column temperature 30***°C*; Gradient Elution; Run time:* 65 ​min.Fig. 3BTable 2Relative response factors (RRF) for quantitative chromatography.Table 2S NoCompound NameRRTRRFResolutionTailing Factor1DSA[a](#tbl2fna){ref-type="table-fn"}0.820.75--1.22CTZ[a](#tbl2fna){ref-type="table-fn"}0.901.042.61.23HCTZ1.001.002.21.14TMS-EP-A[b](#tbl2fnb){ref-type="table-fn"}0.371.279.51.15TMS-EP-E[b](#tbl2fnb){ref-type="table-fn"}0.670.9636.41.16TMS-EP-F[b](#tbl2fnb){ref-type="table-fn"}0.760.898.51.17TMS-EP-B[b](#tbl2fnb){ref-type="table-fn"}0.850.807.61.18TMS1.001.008.71.19TMS-EP-G[b](#tbl2fnb){ref-type="table-fn"}1.100.836.91.110TEL2[b](#tbl2fnb){ref-type="table-fn"}1.170.715.01.111Dimer acid[b](#tbl2fnb){ref-type="table-fn"}1.400.8516.41.212TMS-EP-C[b](#tbl2fnb){ref-type="table-fn"}1.500.625.51.013Chloroanalog[b](#tbl2fnb){ref-type="table-fn"}1.540.943.11.114TEL1[b](#tbl2fnb){ref-type="table-fn"}1.621.326.21.115TMS-EP-H[b](#tbl2fnb){ref-type="table-fn"}1.771.1018.11.0[^1][^2]

2.4. Sample preparation {#sec2.4}
-----------------------

The drug samples and formulation samples were prepared in 0.01 ​M HCl: Methanol (800:200) which is used as a diluent to achieve a concentration of 500 ​μg/mL of TMS and 200 ​μg/mL of HCZ. Impurities spiked sample chromatograms are shown in [Fig. 4A](#fig4a){ref-type="fig"}, [Fig. 4B](#fig4b){ref-type="fig"}.Fig. 4ASpiked sample Chromatogram.Legend: Flow rate 1.0 ​mL/min*, UV Wavelength* 230 ​nm*; injection volume* 10 ​μL; ***Column temperature 30***°C*; Gradient Elution; Run time:* 65 ​min.Fig. 4AFig. 4BSpiked sample Chromatogram with Impurity-D.Legend: Flow rate 1.0 ​mL/min*, UV Wavelength* 230 ​nm*; injection volume* 10 ​μL; ***Column temperature 30***°C*; Gradient Elution; Run time:* 65 ​min.Fig. 4B

3. Results and discussion {#sec3}
=========================

3.1. Method development {#sec3.1}
-----------------------

Based on TMS and HCZ pKa values, acidic mobile phase was selected for initial development trial. Based on the structural polarity nature HCZ and its related impurities may elute in the order of DSA, CTZ and HCZ peak. TMS and its related impurity may elute in the following descending order with reverse phase mobile phase contained octadecyl silane (C18) column. The impurities of HCZ viz. DSA, CTZ are highly polar and tends to elute quickly and requires aqueous mobile phase delivers moderate acidic pH for symmetrical peaks. The initial isocratic mobile phase consisting of 0.02 ​M potassium dihydrogen phosphate buffer solution adjusted to a pH of 4.0 and acetonitrile in the ratio of 750:250. Different kind of buffers (ammonium dihydrogen phosphate, sodium per chlorate) also optimized and found symmetric peaks with the capacity factor of first eluting HCZ impurity ​\> ​3. However, due to the typical non-polar nature of TMS impurity compounds and selectivity among the components of interest, the gradient program is utilized to elute the impurity compounds with optimal required resolution of NLT 1.5. Mobile phase-B preliminarily selected as a mixture of water and acetonitrile in the ratio of 100: 900 v/v respectively. One hundred percent aqueous buffer (mobile phase-A) has been used as initial gradient to retain high polar compounds of HCZ and its impurities, the resulted chromatogram shows that DSA, CTZ and HCZ were well separated from void peak and from each other. Due to the higher aqueous ratio of mobile phase A, partial peak distortion was observed for HCZ peaks and peak symmetry was got affected and corrected by the initial gradient addition of \~ 15% of mobile phase-B to get good symmetrical peaks of polar compounds and this effect also studied with later elution of peaks in the chromatographic development.

Gradually increased the organic phase ratio into HPLC column to elute more retained peaks like TMS and its impurities. Different gradient trials were conducted to elute all the peaks with specific retention for close eluting peaks (TLA1, TMS) with higher % B. The pH of mobile phase A \< 3.5 is evaluated and found that there are 2 impurities (DSA, TEL2) moderately increasing over time from the preparation time of drug product sample. Also this pH study in mobile phase A is extended to neutral (pH ​\~ ​6--7) and slight basic (pH ​\~ ​8--9) conditions, found that any of the stated conditions did not exhibit stability of the % impurities in drug product sample over time due to degradation. Hence, pH of the mobile phase A optimized at pH 3.5.

The resolution of the method has been found critical in separation with various parameters viz. pH of the mobile phase (3.5), column temperature (40) which are enhances the separation sensitivity between the imp-C and imp-B peaks of TMSFrom various column brands as stated above with this chromatographic condition found to be typical separation and one column among them delivers the effective separation for the components of interest. The column Inertsil ODS 3 ​V (150 ​× ​4.6) mm 3.5 ​μm found to be sensitive and selective separation among the peaks (resolution NLT 1.5) at the retention times range from 8 to 15 ​min and 40--50 ​min which is not obtained by any further modification of gradient change, mobile phase composition or various column brands. The elution order of components of interest are presented in [Table 2](#tbl2){ref-type="table"}.

3.2. Software aided method optimization {#sec3.2}
---------------------------------------

Quality by design (QbD) is well established in the development and manufacture of pharmaceutical drug substance and drug product processes as described in ICH Q8, Q9 and Q11. The objective of AQbD is to design a rugged, robust method that consistently delivers the intended performance (*Reid* et al.*, 2013*). Design of Experiments (DoE) is the simple method to optimize the experimental condition with two or more variables (*Anderson and Patrick, 2004; Krull* et al.*, 2009; Monks* et al.*, 2011*). QbD approach is more applied to method development than method validation since method validation is the process of demonstrating that a well-developed analytical method is suitable for its intended purpose. DOE for analytical methods during the development stage is needed for better improvement, a quantitative understanding of the factors that influence resolution, selectivity is an integral part of the method development. Optimized chromatographic conditions were evaluated for Critical Method attributes (CMAs), based on the developmental knowledge and screening studies. viz. buffer pH, flow rate and column temperature.

3.3. Design of experiments {#sec3.3}
--------------------------

The development and optimization of analytical methods with systematic and scientific manner is specified as analytical quality by design (AQbD). The application of AQbD principle during analytical method development and validation shows a significant positive impact of method life cycle. The QbD approach \[[@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31]\] is more applied to method development than method validation since method validation is the process of demonstrating that a well-developed analytical method is suitable for its intended purpose.

Fundamentally, analytical QbD requires identification of analytical target profile (ATP) before the analytical technology is considered. As a next step critical method attributes (CMAs) of the method are identified (for example: flow rate, column temperature and buffer pH) based on developmental knowledge and experiments. Design-of-experiments (DoE) studies were performed to identify design space. CMAs and experimental resulted ATPs been shown in [Table 3](#tbl3){ref-type="table"}. The Three-Level Factorial design was selected with the help of Design expert11 trial version software and executed all the suggested experiments in a randomized manner. The designed model and obtained results with the possible combination studies are shown in [Table 3](#tbl3){ref-type="table"}Table 3Design of Experiments for the optimized chromatographic parameters.Table 3StdRunFactor1Factor2Factor3Response1Response2Response3Flow rateColumn TemperatureBuffer pHResolution btw DSA & CTZResolution btw CTZ & HCTZResolution btw TMS C & Chloro analog1450.8503.52.52.82.91360.8503.52.52.82.91090.8303.52.83.12.96120.8502.52.42.92.95140.8502.52.42.92.92160.8302.52.83.33.19170.8303.52.93.23.11180.8302.52.83.12.817314032.62.92.918414032.62.92.81511.2503.52.32.62.9321.2302.52.42.82.8871.2502.52.32.52.91181.2303.52.42.82.94101.2302.52.52.92.77111.2502.52.42.62.816131.2503.52.42.62.812151.2303.52.52.92.9

3.4. Effects of CMAs on responses {#sec3.4}
---------------------------------

A second-order quadratic polynomial design was selected to identify the significant factors that are influencing the resolutions of selected ATPs, the predefined CMAs ((Flow rate), (column temperature), and (Buffer pH)) are studies as suggested by Design Expert, the total of 18 experiments were conducted are shown in [Table 3](#tbl3){ref-type="table"}. The linear analysis of variance (ANOVA) data shown in [Table 4](#tbl4){ref-type="table"}, depicting the model selected is significant (p-value ​\< ​0.05) to recognize the effects of factors affecting the all three responses resolution.Table 4ANOVA data.Table 4Sum of SquaresdfMean SquareF-valuep-valueResponse 1Model0.451220.225627.11\<0.0001significantA-Flow rate0.225610.225627.110.0001B-column Temp0.225610.225627.110.0001**Response 2**Model0.720020.360090.00\<0.0001significantA-Flow rate0.360010.360090.00\<0.0001B-column Temp0.360010.360090.00\<0.0001**Response 3**Model0.125020.06258.840.0029significantA-Flow rate0.062510.06258.840.0095B-column Temp0.062510.06258.840.0095

3.5. Effect of chromatographic factors on responses {#sec3.5}
---------------------------------------------------

The linear quadratic ANOVA data of response 1 ([Table 4](#tbl4){ref-type="table"}) conforms that flow rate & column temperature (P-value ​\< ​0.0001) are showing highly significant effect on *Resolution between DSA & C*TZ, Chlorothiazide impurity and HCZ peak. The linear quadratic ANOVA data of response 2 ([Table 4](#tbl4){ref-type="table"}) conforms that flow rate & column temperature (P-value ​\< ​0.0095) are showing moderate effect on r*esolution between Telmisartan Impurity C & Chloro analogue* impurity.

4. Method validation {#sec4}
====================

4.1. Method precision and accuracy {#sec4.1}
----------------------------------

Specified amounts of impurity compounds of HCZ, TMS spiked in the stock sample solution and evaluated the compound recoveries using the HPLC technique. Standard computing and recovery analyses were also conducted on the sample to determine the accuracy of the impurity compounds and drug substances (HCZ & TMS). The study was carried out in triplicate (3) preparation using five (5) concentration levels from LOQ -- 0.04% (0.08 ​μg/mL) to 0.5% (1.00 ​μg/mL^)^ for HCZ & it's Impurity compounds where as LOQ -- 0.04% (0.2 ​μg/mL) to 0.5% (2.5 ​μg/mL^)^ for TMS & it's impurity compounds. The % recovery values fall to the linear regression of more than 0.998. Representative chromatograms of the spiked sample preparation are shown in [Table 4](#tbl4){ref-type="table"}.

4.2. Specificity {#sec4.2}
----------------

### 4.2.1. Matrix interferences {#sec4.2.1}

The specificity of the analyte compounds of interest evaluated against the presence of formulation matrix components, diluent used for sample preparation, mobile phase used for chromatographic analysis.

### 4.2.2. Forced degradation {#sec4.2.2}

The stress studies carried out on a drug product to establish its inherent stability characteristics, leading to identification of degradation products and hence supporting the suitability of the proposed analytical procedures. It also requires that analytical test procedures for stability samples should be stability indicating with qualified analytical method validation characteristics. The forced degradation of placebo and formulation was carried out as per ICH guidelines \[[@bib32]\]. The acid (1.7 ​N HCl, refluxed at 60 ​°C for 10 ​h), base (1.7 ​N HCl, refluxed at 60 ​°C for 10 ​h), Peroxide (1.7% H2O2, refluxed at 60 ​°C for 10 ​h) and Water (10 ​mL H2O, refluxed at 60 ​°C for 10 ​h) and thermal (105 ​°C for 24 ​h) stress conditions were studied out by refluxing the drug substance one in the presence of other in matrix formulation. The % impurity evaluation and peak purity results of the stress condition summarized in [Table 5](#tbl5){ref-type="table"}, respectively.Table 5Peak purity Results in stressed condition.Table 5A: For TMS ImpuritiesCompound Name% DegradationMass balancePurity AnglePurity ThresholdPurity flagAs such SampleNA100.00.8471.001NoAcid Degradation (1.7 ​N HCl, refluxed at 60 ​°C for 10 ​h)1.598.50.6131.006NoBase Degradation (1.7 ​N HCl, refluxed at 60 ​°C for 10 ​h)2.697.40.5081.008NoPeroxide degradation (1.7% H~2~O~2~, refluxed at 60 ​°C for 10 ​h)5.294.80.0891.018NoHeat degradation (105 ​°C for 24 ​h)1.498.60.1781.009NoWater degradation (10 ​mL H~2~O, refluxed at 60 ​°C for 10 ​h)0.199.90.1311.009No**B: For HCZ Impurities**Degradation Condition% DegradationMass balancePurity AnglePurity ThresholdPurity flagAs such SampleNA100.00.3760.985NoAcid Degradation (1.7 ​N HCl, refluxed at 60 ​°C for 10 ​h)20.779.30.1071.054NoBase Degradation (1.7 ​N HCl, refluxed at 60 ​°C for 10 ​h)13.286.80.1221.061NoPeroxide degradation (1.7% H2O2, refluxed at 60 ​°C for 10 ​h)23.776.30.1591.83NoHeat degradation (105 ​°C for 24 ​h)12.287.80.2771.170NoWater degradation (10 ​mL H2O, refluxed at 60 ​°C for 10 ​h)11.688.40.0961.075No

4.3. Limits of detection (LOD) and quantification (LOQ) {#sec4.3}
-------------------------------------------------------

The method was observed with a sensitive level of detection of impurities is at 0.025% (\~0.125 ​μg/mL for TMS; \~0.05 ​μg/mL for HCZ) with respect to respective active drug concentration in sample using signal to noise ratio evaluation. The LOQ for HCZ & TMS and its Impurity compounds was determined at a signal-to-noise ratio of 10:1, by inoculating a range of dilute solutions with specified concentrations. LOQ was obtained for the listed impurity compounds at 0.04% level (\~0.2 ​μg/mL for TMS; \~0.08 ​μg/mL for HCZ) with respect to respective active drug concentration in sample. The accuracy study was performed at LOQ level by preparing the six (6) individual spiked preparations, and the % recovery results were summarized in [Table 6](#tbl6){ref-type="table"}.Table 6Accuracy at LOQ evaluation.Table 6S NoImpurity NameLimit of Quantitation (LOQ)Concentration (%)% Recovery[a](#tbl6fna){ref-type="table-fn"}1DSA0.043109.42CTZ0.038104.33HCTZ0.042107.04TMS-EP-A0.037108.95TMS-EP-E0.044113.66TMS-EP-F0.042108.77TMS-EP-B0.040104.88TMS0.041102.69TMS-EP-G0.043107.910TEL20.040108.311Dimer acid0.037103.912TMS-EP-C0.040102.613Chloroanalog0.041103.914TEL10.040104.815TMS-EP-H0.039105.9[^3]

4.4. Linearity {#sec4.4}
--------------

Linear calibration area for the related substance were established at five (5) determinations over the calibration range tested, i.e. LOQ (0.04%) to 0.5% for the listed impurity compounds and drug substance (HCZ and TMS) as an unspecified impurity compound. Linearity analysis solutions were prepared by diluting the pure stock solutions of the drug substance and impurities to the expected concentrations. As such, the solutions were fixed at five (5) concentration levels from LOQ to 150% of the specification level (LOQ-0.04%, 0.10, 0.20, 0.30 and 0.50%) for Impurity compounds, HCZ and TMS (unspecified). The linear regression coefficient was found \>0.998. Calibration graphs were plotted by analysis of each calibration solutions. The peak area against the concentration data was treated by least-squares linear regression analysis.

4.5. Stability of mobile phase & sample solutions {#sec4.5}
-------------------------------------------------

The stability of HCZ, TMS and Impurity compounds in the precision spiked sample solution evaluated at room temperature at every 24 ​h frequency intervals up to 72 ​h with the fresh preparation of mobile phase every time. The stability of mobile phase was also determined by analyzing freshly prepared precision spiked sample solution at every 24 ​h frequency intervals and found sample, standard and mobile phase solutions were stable up to 48 ​h ​at room temperature.

5. Conclusion {#sec5}
=============

The method provides selective quantification of TMS and HCZ impurities without interference of blank, placebo, thereby affirming the stability-indicating nature of the method. The proposed method is highly selective, reproducible, specific and rapid and the developed method was robust for the separation and quantification of Telmisartan and Hydrochlorothiazide in Telmisartan and Hydrochlorothiazide tablets. The practical impurity results for the 6 various drug product sample batches were evaluated with this methodology and found to be ​≦ ​0.04% (LOQ) for the subject specified and unspecified impurities of HCZ & TMS except DSA, TEL2 and TMS-A, which were observed at ​≦ ​0.1%.
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[^1]: Relative Retention Time (RRT) and RRF with respect to HCTZ peak.

[^2]: RRT and RRF with respect to TMS peak.

[^3]: Determined on 6 homogeneous sample preparations.
